Form 4: Biogen Director Maria Freire Receives Stock Grant

Biogen Inc. director Maria C. Freire was granted 2,005 restricted stock units as part of standard equity compensation.

Summary

• Director Maria C. Freire acquired 2,005 shares of Biogen Inc. (BIIB) common stock via a restricted stock unit grant.
• The transaction occurred on June 9, 2026, at a price of $0 per share.
• Following this transaction, Dr. Freire's total beneficial ownership in the company increased to 8,820 shares.
• The restricted stock units are subject to vesting conditions based on the next annual meeting or the one-year anniversary of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock units will vest on the earlier of the next annual meeting or June 9, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for large-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 2,005 restricted stock units upon the next annual meeting or the one-year anniversary of the grant.

Key Dates

Keywords

Biogen, BIIB, Form 4, Insider Trading, Equity Compensation, Director